Panacos reiterated at outperform by RBC

Panacos Pharmaceuticals Inc. was reiterated at outperform, speculative risk, by RBC Capital Markets analyst Jason Kantor on concerns related to the company's early results from the phase 2b trial of PA-457 (now called bevirimat) for HIV could be difficult to interpret. The analyst anticipates positive data demonstrating clear efficacy, safety and a dose response with once-daily PA-457. The company also reported second-quarter results in line with the analyst's expectations. Shares of the Watertown, Mass.-based biotechnology company were down 41cents, or 8.56%, at $4.38, on volume of 579,995 shares versus the three-month running average of 558,116 shares. (Nasdaq: PANC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.